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Abstract
Background: Although the prognostic biomarkers associated with colorectal cancer (CRC) survival are well known,
there are limited data on the association between the molecular characteristics and survival after recurrence (SAR).
The purpose of this study was to assess the association between pathway mutations and SAR.
Methods: Of the 516 patients with stage III or high risk stage II CRC patients treated with surgery and adjuvant
chemotherapy, 87 who had distant recurrence were included in the present study. We analyzed the association
between SAR and mutations of 40 genes included in the five critical pathways of CRC (WNT, P53, RTK-RAS, TGF-β,
and PI3K).
Results: Mutation of genes within the WNT, P53, RTK-RAS, TGF-β, and PI3K pathways were shown in 69(79.3%),
60(69.0%), 57(65.5%), 21(24.1%), and 19(21.8%) patients, respectively. Patients with TGF-β pathway mutation were
younger and had higher incidence of mucinous adenocarcinoma (MAC) histology and microsatellite instability-high.
TGF-β pathway mutation (median SAR of 21.6 vs. 44.4 months, p = 0.021) and MAC (20.0 vs. 44.4 months, p = 0.003)
were associated with poor SAR, and receiving curative resection after recurrence was associated with favorable SAR
(Not reached vs. 23.6 months, p < 0.001). Mutations in genes within other critical pathways were not associated
with SAR. When MAC was excluded as a covariate, multivariate analysis revealed TGF-β pathway mutation and
curative resection after distant recurrence as an independent prognostic factor for SAR. The impact of TGF-β
pathway mutations were predicted using the PROVEAN, SIFT, and PolyPhen-2. Among 25 mutations, 23(92.0%)-
24(96.0%) mutations were predicted to be damaging mutation.
Conclusions: Mutation in genes within TGF-β pathway may have negative prognostic role for SAR in CRC. Other
pathway mutations were not associated with SAR.
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Background
Colorectal cancer (CRC) is ranked third in cancer inci-
dence and second in cancer-related mortality worldwide
[1]. CRC is a heterogeneous disease, and recent data
from gene expression profiling have classified CRC into
four consensus molecular subtypes (CMSs) [2]. In
addition, integrated analysis of somatic mutations, copy
number change, and mRNA expression from the Cancer
Genome Atlas (TCGA) revealed that the WNT, P53,
RTK-RAS, TGF-β, and PI3K pathways are frequently al-
tered in CRC [3, 4].
The current standard care in stage III CRC is complete
resection of the tumor followed by adjuvant chemotherapy
with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)
or capecitabine plus oxaliplatin (XELOX) [5, 6]. However,
approximately 30% of patients develop recurrence despite
receiving adjuvant chemotherapy [7]. Several biomarkers,
including microsatellite instability-high (MSI-H), the CpG
island methylator phenotype (CIMP), KRAS mutation,
and BRAF mutation, are associated with recurrence and
survival in CRC patients [8–11]. Although the prognostic
biomarkers associated with cancer recurrence are well
studied, there is a paucity of data regarding biomarkers as-
sociated with survival after recurrence (SAR). Recently,
from a study population of stage III CRC patients enrolled
in a phase III adjuvant chemotherapy study, MSI-H was
associated with improved SAR, and KRAS mutation and
BRAF mutation were associated with poor SAR [12].
We have previously reported that mutation in genes
within PI3K pathway is associated with better RFS and
that mutation in genes within RTK-RAS pathway is asso-
ciated with worse RFS in CRC treated with adjuvant
chemotherapy [13]. The purpose of this study was to
evaluate the association between five critical pathway mu-
tations and SAR in CRC patients who had distant recur-
rence after the treatment of curative surgery followed by
adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Methods
Patients and treatment
The study population consisted of patients with stage III
or high-risk stage II CRC who developed distant recur-
rence after receiving curative surgery at Seoul National
University Hospital (SNUH, Seoul, South Korea). All pa-
tients were included in the CRC patient cohort reported
previously [13]. Patients received at least 6 cycles of ad-
juvant FOLFOX or 4 cycles of adjuvant XELOX chemo-
therapy. Upper rectal cancer patients were included if
they did not receive pre- or post-operative radiation
therapy. Exclusion criteria were the following: signet ring
cell histology, anti-EGFR or anti-VEGF treatment for ad-
juvant chemotherapy, history of other malignancy within
5 years, and local recurrence only. Adjuvant FOLFOX
was planned for 12 cycles and XELOX chemotherapy
was planned for 8 cycles. 50 patients received
FOLFOX-4, 27 received FOLFOX-6, and 10 received
XELOX. Electronic database and electronic medical rec-
ord system of SNUH was used to identify eligible pa-
tients and review their medical charts.
Molecular testing, including targeted sequencing of 40
genes associated with five critical pathways
Every exon of the 40 genes associated with the five crit-
ical pathways of CRC was sequenced [13]. Fourteen
genes were selected from WNT pathway (ARID1A,
AMER1, APC, AXIN2, CTNNB1, DKK1, DKK2, DKK3,
DKK4, FBXW7, FZD10, LRP5, SOX9, TCF7L2), 2 genes
from P53 pathway (ATM, TP53), 8 genes from RTK-RAS
pathway (BRAF, EGFR, ERBB2, ERBB3, ERBB4, HRAS,
KRAS, NRAS), 7 genes from TGF-β pathway (ACVR1B,
ACVR2A, SMAD2, SMAD3, SMAD4, TGFBR1,
TGFBR2), and 9 genes from PI3K pathway (IGF1R,
IGF2, IRS2, MTOR, PDGFRA, PIK3CA, PIK3R1, PTEN,
SRC). Detailed methods for targeted sequencing can be
found in our previous article [13]. Briefly, genomic DNA
(> 200 ng) samples were sheared and prepared according
to routine library preparation. The captured library was
amplified and sequenced using Hiseq 2500 (Illumina,
USA). Sequencing data were filtered with a mean quality
Q20 (Phred score) per read, and these filtered data were
aligned to GRCh37 using bwa 0.7.5a. The aligned reads
were processed with Picard Mark Duplicates and GATK
base recalibration. After a series of processes, the aligned
bases were piled up with SAM tools. Variant call and
somatic analysis processes were performed by Varscan
and were annotated with ANNOVAR. The pathways
were defined as having a mutation if any gene included
in the pathway had a mutation.
The microsatellite status was assessed using the fol-
lowing markers: BAT25, BAT26, D2S123, D5S346 and
D17S250 [13]. Instability at 2 or more markers were de-
fined as MSI-high, 1 as MSI-low, and 0 as MSS. MSI-H
was regarded as having MSI, and MSI-L was grouped
with MSS.
Statistical analysis
The primary objective of this study was to investigate
the effect of mutations of critical pathways and
clinico-pathologic characteristics on SAR. SAR was de-
fined as the time from distant tumor recurrence to death
from any cause. Categorical variables were compared by
chi-square test or Fisher’s exact test. Continuous vari-
ables were compared using the independent-samples T
test. SAR was calculated using the Kaplan-Meier
method, and comparisons were made using log-rank
tests. Hazard ratios (HRs) were calculated using the Cox
proportional hazard model. To adjust for the baseline
characteristics, Cox proportional hazard analysis of SAR
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included sex, age (continuous variable), tumor location
[proximal (from the cecum to the transverse colon) vs.
distal (from the descending colon to the rectum)], tumor
histology (mucinous adenocarcinoma vs. non-mucinous
adenocarcinoma), tumor (T) stage (continuous variable),
lymph node (N) stage (continuous variable), curative op-
eration (done vs. not done), recurrence before 1 year,
microsatellite status (MSI-high vs. MSS and MSI-low),
and five critical pathway mutations. Two-sided p-values
less than 0.05 were considered statistically significant.
Statistical analysis was performed using SPSS software
for Windows, version 20.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
At a median follow-up duration of 44.4 months, 87 pa-
tients had distant recurrence among our database of 516
patients [13]. The baseline characteristics of the 87 pa-
tients are summarized in Table 1. The primary tumor lo-
cation was proximal (from the cecum to the transverse
colon) in 28 patients (32.2%) and distal (from the de-
scending colon to the rectum) in 59 patients (67.8%).
Nine patients (10.3%) had MAC histology, and 3 patients
(3.5%) showed MSI-H feature.
After distant recurrence, palliative chemotherapy was
introduced in 77 (88.5%) patients. The first-line chemo-
therapy regimens included FOLFIRI in 56 patients, cape-
citabine monotherapy in 8, FOLFIRI plus bevacizumab
in 7, FOLFIRI plus cetuximab in 2, FOLFOX in 2, S-1
plus oxaliplatin in 1, and capecitabine plus irinotecan in
1. Second-line chemotherapy was administered to 47
(54.0%) patients. Only 1 patient received both bevacizu-
mab and cetuximab during the course of treatment. In
total, 9 (10.3%) patients received bevacizumab and 9
(10.3%) patients received cetuximab during their course
of treatment.
Gene mutation and pathway mutation
In patients with recurrence, mutations were most fre-
quently found in TP53 (65.5%) followed by APC (64.4%),
KRAS (48.3%), FBXW7 (16.1%), and SMAD4 (10.3%)
(Additional file 1: Table S1). The WNT pathway was
mutated in 79.3%, P53 in 69.0%, RTK-RAS in 65.5%,
TGF-β in 24.1%, and PI3K in 21.8% of patients. The mu-
tation frequencies of most genes were similar between








Age Median (range) 59 (31–75) 61 (38–75) 54 (31–74) 0.020
Sex Male 50 (57.5%) 36 (54.4%) 14 (66.7%) 0.33
Female 37 (42.5%) 30 (45.5%) 7 (33.3%)
Location Proximal 28 (32.2%) 19 (28.8%) 9 (42.9%) 0.23
Distal 59 (67.8%) 47 (71.2%) 12 (57.1%)
Stage II, high-risk 14 (16.1%) 8 (12.1%) 6 (28.6%) 0.074
III 73 (83.9%) 58 (87.9%) 15 (71.4%)
T stage 1 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.41
2 1 (1.1%) 1 (1.5%) 0 (0.0%)
3 62 (71.3%) 49 (74.2%) 13 (61.9%)
4 24 (27.6%) 16 (24.2%) 8 (38.1%)
N stage 0 14 (16.1%) 8 (12.1%) 6 (28.6%) 0.18
1 29 (33.3%) 24 (36.4%) 5 (23.8%)
2 44 (50.6%) 34 (51.5%) 10 (47.6%)
Histology Non-MAC 78 (89.7%) 65 (98.5%) 13 (61.9%) < 0.001
MAC 9 (10.3%) 1 (1.5%) 8 (38.1%)
MSI MSS/MSI-L 83 (96.5%) 65 (100.0%) 18 (85.7%) 0.013
MSI-H 3 (3.5%) 0 (0.0%) 3 (14.3%)
Time to recurrence < 1 year 19 (21.8%) 11 (16.7%) 8 (38.1%) 0.038
≥1 year 68 (78.2%) 55 (83.3%) 13 (61.9%)
Curative resection after distant recurrence Not done 52 (59.8%) 39 (59.1%) 13 (61.9%) 0.82
Done 35 (40.2%) 27 (40.9%) 8 (38.1%)
Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
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the patients with recurrence and without recurrence
(Additional file 1: Table S1). The mutation frequency of
PIK3CA and CTNNB1 was lower in the patients with re-
currence, and APC showed a tendency of lower fre-
quency in patients with recurrence. PI3K pathway
mutation showed a tendency of lower frequency in pa-
tients with recurrence.
Patients with mutation in genes within TGF-β pathway
showed distinct characteristics compared with patients
without TGF-β pathway mutation (Table 1). Patients
with TGF-β pathway mutation was associated with a
younger age (median age of 54 years vs. 61 years, p =
0.020), and there was a tendency of a higher percentage
of patients with initial high-risk stage II disease (28.6%
vs. 12.1%, p = 0.074). Moreover, patients with TGF-β
pathway mutation had a higher incidence of MSI-H and
MAC. All 3 patients with recurrence in MSI-H had
TGF-β pathway mutation. In addition, the incidence of
TGF-β pathway mutation was 88.9% (8/9) in MAC pa-
tients compared with 16.7% (13/78) in non-MAC pa-
tients (p < 0.001) (Additional file 1: Table S2). The
mutation incidences of other pathways were similar be-
tween MAC and non-MAC histology (Additional file 1:
Table S2).
Prognostic role of five critical pathways
Among the 87 patients who had distant recurrence, 40
death events occurred with an estimated median SAR of
38.2 months. SAR was significantly worse in patients
with TGF-β pathway mutation than in those with wild
type (median SAR of 21.6 vs. 44.4 months, p = 0.021)
(Fig. 1). In our previous report, mutation in genes within
PI3K pathway was associated with a longer RFS, whereas
mutation in genes within RTK-RAS pathway was associ-
ated with a shorter RFS [13]. However, there was no cor-
relation between SAR and other critical pathway
mutations (Additional file 2: Figure S1). In addition to
TGF-β pathway mutation, curative resection after distant
recurrence and MAC was associated with poor SAR,
and N2 stage showed a tendency of poor SAR (Table 2).
Tumor location and MSI were not associated with SAR.
Multivariate analysis using the Cox proportional hazard
model revealed that curative resection after distant re-
currence [adj HR for SAR 0.27 (95% CI 0.13–0.56), p =
0.001] and MAC histology [adj HR for SAR 3.77 (95%
CI 1.52–9.35), p = 0.004] were independent prognostic
factors for SAR. In the present study, MAC histology
showed a higher incidence of TGF-β pathway muta-
tion compared to non-MAC histology (88.9% vs.
16.7%, p < 0.001) (Additional file 1: Table S2). Al-
though statistically not significant, the negative prog-
nostic role of TGF-β pathway mutation was
maintained in patients with non-MAC histology (me-
dian SAR of 36.7 vs. 44.4 months, p = 0.127) (Fig. 2).
After removing MAC histology as a covariate, multi-
variate analysis revealed TGF-β pathway mutation [adj
HR for SAR 1.99 (95% CI 1.02–3.90), p = 0.044] and
curative resection after distant recurrence [adj HR for
SAR 0.28 (95% CI 0.13–0.59), p = 0.001] as independ-
ent prognostic factors for SAR.
We next analyzed whether individual gene muta-
tion is associated with SAR (Additional file 1: Table
S2). Patients with SMAD4 mutation had worse SAR
compared to wild type (SAR of 17.6 months vs. 38.7
months, p = 0031) and those with APC mutation had
a tendency of favorable SAR compared to wild type
(SAR of 45.6 months vs. 28.1 months, p = 0070). In
the multivariate analysis, SMAD4 mutation was an
independent negative prognostic factor for SAR [ad-
justed hazard ratio (adj HR) for SAR 3.54 (95% CI
1.13–11.03), p = 0.030]. The detailed mutation profile
of TGF-β pathway is shown in Table S4 (Additional
file 1: Table S4). Among 25 mutations, 5 were stop
gain mutation, 4 were frame shift deletion mutation,
and 2 were non-frameshift deletion mutation which
would probably lead to loss of expression. Impact of
14 non-synonymous SNV in TGF-β pathway muta-
tion was predicted using the PROVEAN, SIFT, and
PolyPhen-2 (Additional file 1: Table S2) [14–16].
Among 14 non-synonymous SNV, 12(85.7%)-
13(92.9%) were predicted to be damaging mutation
(Additional file 1: Table S4). In total, 23(92.0%)-
24(96.0%) mutations were predicted to be damaging
mutation in the TGF-β pathway. We also predicted
functional outcome of SMAD4 mutations using the
OncoKB database (Additional file 1: Table S4) [17].
Among 9 SMAD4 mutations, 3 mutations were
Fig. 1 TGF-β pathway mutation and survival after recurrence
Lee et al. BMC Cancer          (2019) 19:421 Page 4 of 8
found to be loss-of-function and additional 2 muta-
tions involved the same location with aforemen-
tioned loss-of-function mutation. ACVR1B and
ACVR2A genes were not covered by the OncoKB
and our mutation involving SMAD2, SMAD3,
TGFBR1, and TGFBR2 was not reported in the
OncoKB.
Discussion
This study revealed that mutation in genes within TGF-β
pathway is associated with MAC and may have poor SAR
in colorectal cancer patients. Other critical pathways were
not associated with SAR. In our previous study, mutation
in genes within TGF-β pathway was not associated with
RFS [13]. This implicates that while TGF-β pathway muta-
tion is not associated with recurrence in early-stage tu-
mors, it may be fatal in later-stage tumors.
In the present study, patients with TGF-β pathway mu-
tation had higher incidence of MAC. This is in line with
data from the TCGA where TGF-β pathway is more fre-
quently altered in MAC histology compared to non-MAC
histology (67.9% vs. 30.6%, p < 0.001) [18]. The TGF-β
pathway is associated with cell proliferation, cell differenti-
ation, apoptosis, and epithelial-mesenchymal transition
(EMT) [19, 20]. Although mutational inactivation of TGF-
β pathway is frequently shown in colorectal cancer, the
level of TGF-b production is somehow elevated in later
stage tumor [21, 22]. One of the reasons is that TGF-b
level is not only affected by tumor but is also affected by
stromal cells [22, 23]. The correlation between TGF- β
pathway mutation (which is usually loss-of function) and
TGF-b level has not been clearly identified and maybe
Table 2 Univariate analysis of survival after recurrence
Variable Median SAR (months) p-value
Age < 65 years 36.7 (26.0–47.3) 0.71
≥65 years 45.6 (29.4–61.8)
Sex Male 37.8 (33.6–42.1) 0.49
Female 55.4 (0.0–110.8)
Location Proximal 37.8 (13.9–61.8) 0.82
Distal 38.7 (27.9–49.4)
Time to recurrence < 1 year 31.7 (5.9–57.6) 0.16
≥1 year 44.4 (31.4–57.4)
Stage II, high risk 49.7 (N/A) 0.36
III 37.8 (30.2–45.5)
T-stage T1–3 38.2 (29.0–47.4) 0.31
T4 28.1 (0.0–64.8)
N-stage N0–1 49.7 (26.1–73.3) 0.064
N2 29.3 (11.4–47.3)
Histology Non-MAC 44.4 (31.2–54.7) 0.003
MAC 20.0 (4.9–35.0)
Curative resection after distant recurrence Not done 23.6 (12.1–35.2) < 0.001
Done Not reached
MSI MSS/MSI-L 38.2 (28.2–48.2) 0.35
MSI-H 9.3 (1.7–38.2)
Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, N/A not available
Fig. 2 TGF-β pathway mutation and survival after recurrence in
Non-MAC patients. Abbreviations: MAC, mucinous adenocarcinoma
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different among disease status. In terms of clinical rele-
vance, there are reports showing that TGF-β pathway may
have a prognostic role in CRC. CMS classifies colorectal
cancer based on the gene expression profile [2]. CMS4,
which is characterized by the upregulation of genes impli-
cated in EMT, prominent TGF-β pathway activation, stro-
mal invasion, and angiogenesis, is associated with a worse
prognosis. In addition, preclinical studies show that activa-
tion of TGF-β pathway may be linked to chemotherapy re-
sistance in CRC cell line [24, 25]. Recombinant TGF-β
treatment caused chemotherapy resistance in CRC cell
lines [24]. However, TGF-β pathway mutation was not as-
sociated with RFS in CRC patients treated with adjuvant
FOLFOX/XELOX chemotherapy, which we have previ-
ously reported [13]. Discordance in the prognostic role of
TGF-β pathway mutation among disease status could be
partially explained by the fact that the response to TGF-β
pathway activation is different according to cell type and
status [20, 26]. There are opposite effects of the TGF-β
pathway in that it may suppress the growth of tubular ad-
enoma but may promote the tumor growth of sessile ser-
rated adenomas by inducing EMT and metastasis [20, 26].
Apoptosis is the dominant feature after TGF-β pathway
stimulation in classical tubular adenoma organoid culture
[26]. By contrast, inducing EMT is the main outcome after
TGF-β pathway stimulation in an organoid culture model
for sessile serrated adenomas [26]. The activation of
TGF-β may suppress the growth of tubular adenoma but
may progress sessile serrated adenomas to CMS4 subtype
cancer by inducing EMT [26]. Moreover, evidence show
that TGF-b level is also affected by stromal cells [22].
While TGF-β pathway mutation is not associated with
RFS in CRC patients treated with adjuvant FOLFOX/
XELOX chemotherapy, it may be fatal in CRC patients
who have recurred after curative surgery. Among the
genes involved in the TGF-β pathway, SMAD4 mutation
was associated with poor SAR. SMAD4 is a tumor sup-
pressor gene and its mutation is involved in advanced
stages, such as distant metastasis, in human colorectal car-
cinogenesis [27]. In the present study, we predicted out-
come of TGF-β pathway mutation using the PROVEAN,
SIFT, and PolyPhen-2. Among 14 non-synonymous SNV
in TGF-β pathway mutation 12(85.7%)-13(92.9%) were
predicted to be damaging mutation. Other 11 muta-
tions consisted of 5 stop gain mutation, 4 frame shift
deletion mutation, and 2 non-frameshift deletion mu-
tation which would probably lead to loss of expres-
sion. In sum, 23(92.0%)-24(96.0%) mutations were
predicted to be damaging mutation in the TGF-β
pathway. In addition, all SMAD4 mutations reported
in the OncoKB database were loss-of-function muta-
tion. This shows that TGF-β pathway mutation may
have contributed to poor SAR due to loss of function.
The correlation between TGF-β pathway mutation,
TGF-b expression, and chemotherapy resistance needs
to be studied in the future.
Sinicrope et al. reported that MSI-H is associated with
improved SAR and that KRAS mutation and BRAF mu-
tation are associated with poor SAR in stage III colon
cancer patients treated with adjuvant chemotherapy
[12]. However, we could not evaluate the role of MSI-H
and BRAF mutation in SAR because there were only 3
patients with MSI-H and 5 patients with BRAF V600E
mutation. In contrast to a study by Sinicrope et al.,
RTK-RAS pathway mutation and KRAS exon 2 mutation
were not associated with SAR in the present study. In a
study by Sinicrope et al., the negative prognostic role of
KRAS mutation was limited to patients who received ad-
juvant FOLFOX pus cetuximab but not in patients
treated with adjuvant FOLFOX alone. In the present
study, none of the patients received cetuximab in the ad-
juvant setting. This implicates that KRAS mutation may
not affect SAR in patients treated with adjuvant FOL-
FOX or XELOX alone.
The major limitation of this study was that we did not
evaluate genetic characteristics other than targeted se-
quencing of genes associated with 5 critical pathways. Al-
though major genes included in the TGF-β pathway were
sequenced, other alterations, including copy number vari-
ation or the expression level, were not analyzed. It is also
important to analyze the TGF-β pathway induced by stro-
mal cells [3, 23]. Therefore, comprehensive analysis of the
TGF-β pathway could provide a better understanding of
CRC biology in the future. Another limitation of the
present study was that patients were treated differently
after recurrence. However, this study was performed at a
high-volume single center where the treatment plan was
relatively uniform. The last limitation was the relatively
small number of patients included in this cohort. How-
ever, this was the first study to evaluate the relationship
between pathway mutation and SAR in CRC patients.
Conclusions
This study revealed that CRC patients with mutation in
genes within TGF-β pathway may have poor SAR. Other
pathway mutations were not associated with SAR. Future
works on the relationship between TGF-β pathway mutation
and survival according to disease status needs to be studied.
Additional files
Additional file 1: Table S1. Mutation rate of 40 genes included in the
study. Table S2. Mutation rate of critical pathways according to
histology. Table S3. Survival after recurrence according to each gene
mutation. (Genes with mutation rate over 5%). Table S4. Detailed profile
of TGF-β pathway mutation. (DOCX 60 kb)
Additional file 2: Figure S1. Pathway mutations and survival after
recurrence. Mutation in pathways other than TGF-β were not associated
with survival after recurrence. (TIF 311 kb)
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